425: TenX Keane Acquisition Extends Business Combination Deadline with $66,667 Contribution from Citius Pharma

TenX Keane Acquisition secures a one-month extension for its business combination deadline through a $66,667 contribution from Citius Pharmaceuticals, evidenced by a promissory note.

Summary

• TenX Keane Acquisition has extended its deadline to consummate a business combination by one month, from April 18, 2024, to May 18, 2024.
• This extension was facilitated by a $66,667 deposit into the company's trust account by Citius Pharmaceuticals.
• The deposit was made in accordance with the terms of the Merger Agreement between TenX Keane Acquisition and Citius Pharmaceuticals.
• The deposit is documented by an unsecured promissory note issued by TenX Keane Acquisition to Citius Pharmaceuticals, bearing no interest.
• The note is repayable in full per the terms of the Merger Agreement.
• TenX Keane Acquisition can extend the period of time to consummate a business combination up to seven times for an additional one month each time from April 18, 2024 to November 18, 2024, if requested by 10XYZ Holdings LP, the sponsor of the Company.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an extension is needed, the commitment from Citius Pharma to provide funds is a positive sign. However, the need for an extension introduces some uncertainty.

Positives

• TenX Keane Acquisition secured an extension to complete its business combination, indicating continued efforts to finalize the deal.
• Citius Pharmaceuticals' willingness to provide the $66,667 contribution demonstrates their commitment to the merger.
• The extension provides additional time to meet the conditions for the business combination.

Negatives

• The need for an extension suggests potential challenges in completing the business combination within the original timeframe.
• The $66,667 contribution represents a cost to Citius Pharma, although it is structured as a repayable note.
• The extension is only for one month, and further extensions may be required, potentially adding more costs.

Risks

• Failure to complete the business combination by the extended deadline could lead to further extensions and associated costs.
• If the balance of the Trust Account does not equal or exceed $2,000,000 at the time of closing, the Payee understands that this Note will not be repaid.
• There is a risk that the conditions for repayment of the promissory note may not be met, potentially impacting Citius Pharmaceuticals' financial position.

Future Outlook

The company has the option to extend the business combination deadline up to seven times, each for an additional month, until November 18, 2024, subject to additional contributions from the Sponsor or its designee.

Industry Context

The announcement reflects the ongoing trend of SPACs (Special Purpose Acquisition Companies) seeking extensions to complete mergers, often requiring additional capital injections to maintain their trust accounts and extend timelines. The willingness of Citius Pharma to provide funds suggests a strong commitment to the merger despite potential delays.

Comparison to Industry Standards

• SPAC extensions are common, with many SPACs needing to inject funds to extend their lifespan.
• The size of the contribution ($66,667) is relatively small compared to the overall deal size, but it is typical for monthly extensions.
• Other SPACs, such as Gores Metropoulos II, have also faced extension deadlines and required sponsor contributions to extend their timelines.

Related Party Transactions

• The deposit of $66,667 by Citius Pharma into TenX Keane Acquisition's trust account and the issuance of the promissory note represent a related party transaction due to the pending merger agreement.

Stakeholder Impact

• Shareholders of TenX Keane Acquisition may experience a delay in the completion of the business combination.
• Citius Pharmaceuticals is impacted by the financial commitment to extend the deadline.
• The extension provides more time for both companies to finalize the merger, potentially benefiting all stakeholders in the long run.

Next Steps

• TenX Keane Acquisition needs to continue working towards completing the business combination with Citius Oncology.
• Citius Pharmaceuticals will monitor the progress of the merger and ensure the conditions for repayment of the promissory note are met.
• The company may need to seek further extensions if the business combination is not completed by May 18, 2024.

Key Dates